Phase 2Completed
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Industry)
- Enrollment
- 156 enrolled
- Conditions
- Hypercholesterolemia and Mixed Hyperlipidemia
- Interventions
- SYH2053/placebo injection; Inclisiran (Leqvio®) 300mg
- Ages
- adults, older adults
- Registry
- NCT07421232
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
Primary outcomes
- Percentage change in LDL-C relative to baseline
History
Registered
Study completion
Primary completion
Started